This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, S.-C.
Right arrow Articles by Shieh, W.-B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, S.-C.
Right arrow Articles by Shieh, W.-B.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2000, p. 2715-2718, Vol. 44, No. 10
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Clinical Correlates of Antifungal Macrodilution Susceptibility Test Results for Non-AIDS Patients with Severe Candida Infections Treated with Fluconazole

Sai-Cheong Lee,1,* Chang-Phone Fung,2 Jen-Seng Huang,3 Chi-Jen Tsai,3 Kuo-Su Chen,3 Huang-Yang Chen,4 Ning Lee,5 Lai-Chu See,6 and Wen-Ben Shieh3

Division of Infectious Diseases,1 Department of Internal Medicine,3 Department of General Surgery,4 and Department of Pathology,5 Chang Gung Memorial Hospital, Keelung, Department of Public Health, Chang Gung University, Linkou,6 and Division of Infectious Diseases, Veterans General Hospital, Taipei,2 Taiwan, Republic of China

Received 4 April 2000/Returned for modification 26 May 2000/Accepted 6 July 2000

Although the clinical correlates of the reference antifungal susceptibility test results in hematogenous and deep-seated Candida infection are still controversial, we evaluated the clinical correlates of this test in deep-seated Candida infections in non-AIDS patients. Thirty-two non-AIDS patients with hematogenous or deep-seated Candida infections were treated with intravenous fluconazole (400 mg a day), and the clinical outcomes were evaluated. Coexisting bacterial infections were treated with appropriate antibiotics, superinfection or reinfection was excluded, inadequate fluconazole therapy was avoided, and essential surgical intervention was performed. The MICs of fluconazole for these 32 Candida isolates were determined according to the M27-A procedure approved by the National Committee on Clinical Laboratory Standards. MICs were interpreted as susceptible (<= 8 µg/ml), dose-dependent susceptible (16 to 32 µg/ml), and resistant (>= 64 µg/ml) according to the criteria of the M27-A standard. The success rates were 79% (19 of 24; 95% confidence interval [CI], 59 to 93%) in the susceptible category, 66% (4 of 6; 95% CI, 19 to 95%) in the dose-dependent susceptible category, and 0% (0 of 2; 95% CI, 0 to 84%) in the resistant category. We conclude that the clinical correlation of the reference antifungal susceptibility test results is high in hematogenous and deep-seated Candida infections.

* Corresponding author. Mailing address: Division of Infectious Diseases, Chang Gung Memorial Hospital, 222 Mai Chin Rd., Keelung, Taiwan, Republic of China. Phone: 886-02-24313131. Fax: 886-02-24332882. E-mail: Ruby800{at}adm.cgmh.com.tw.

Antimicrobial Agents and Chemotherapy, October 2000, p. 2715-2718, Vol. 44, No. 10
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Arendrup, M. C., Cuenca-Estrella, M., Donnelly, J. P., Lass-Florl, C., Rodriguez-Tudela, J. L., Baddley, J. W., Ostrosky-Zeichner, L., Bhavnani, S. M., Andes, D. R. (2009). Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia. Antimicrob. Agents Chemother. 53: 2704-2706 [Full Text]  
  • Baddley, J. W., Patel, M., Bhavnani, S. M., Moser, S. A., Andes, D. R. (2008). Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia. Antimicrob. Agents Chemother. 52: 3022-3028 [Abstract] [Full Text]  
  • Goodwin, M. L., Drew, R. H. (2008). Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 61: 17-25 [Abstract] [Full Text]  
  • Foster, N., Symes, C., Barton, R., Hobson, R. (2007). Rapid identification of Candida glabrata in Candida bloodstream infections. J Med Microbiol 56: 1639-1643 [Abstract] [Full Text]  
  • Rodriguez-Tudela, J. L., Almirante, B., Rodriguez-Pardo, D., Laguna, F., Donnelly, J. P., Mouton, J. W., Pahissa, A., Cuenca-Estrella, M. (2007). Correlation of the MIC and Dose/MIC Ratio of Fluconazole to the Therapeutic Response of Patients with Mucosal Candidiasis and Candidemia. Antimicrob. Agents Chemother. 51: 3599-3604 [Abstract] [Full Text]  
  • Pai, M. P., Turpin, R. S., Garey, K. W. (2007). Association of Fluconazole Area under the Concentration-Time Curve/MIC and Dose/MIC Ratios with Mortality in Nonneutropenic Patients with Candidemia. Antimicrob. Agents Chemother. 51: 35-39 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Sheehan, D. J. (2006). Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing. Clin. Microbiol. Rev. 19: 435-447 [Abstract] [Full Text]  
  • Clancy, C. J., Yu, V. L., Morris, A. J., Snydman, D. R., Nguyen, M. H. (2005). Fluconazole MIC and the Fluconazole Dose/MIC Ratio Correlate with Therapeutic Response among Patients with Candidemia. Antimicrob. Agents Chemother. 49: 3171-3177 [Abstract] [Full Text]  
  • Andes, D., Marchillo, K., Conklin, R., Krishna, G., Ezzet, F., Cacciapuoti, A., Loebenberg, D. (2004). Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis. Antimicrob. Agents Chemother. 48: 137-142 [Abstract] [Full Text]  
  • Andes, D., Marchillo, K., Stamstad, T., Conklin, R. (2003). In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model. Antimicrob. Agents Chemother. 47: 3165-3169 [Abstract] [Full Text]  
  • Andes, D. (2003). In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis. Antimicrob. Agents Chemother. 47: 1179-1186 [Full Text]  
  • Andes, D., Marchillo, K., Lowther, J., Bryskier, A., Stamstad, T., Conklin, R. (2003). In Vivo Pharmacodynamics of HMR 3270, a Glucan Synthase Inhibitor, in a Murine Candidiasis Model. Antimicrob. Agents Chemother. 47: 1187-1192 [Abstract] [Full Text]  
  • Andes, D., Marchillo, K., Stamstad, T., Conklin, R. (2003). In Vivo Pharmacodynamics of a New Triazole, Ravuconazole, in a Murine Candidiasis Model. Antimicrob. Agents Chemother. 47: 1193-1199 [Abstract] [Full Text]  
  • Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., Warnock, D. W. (2001). Antifungal Susceptibility Testing: Practical Aspects and Current Challenges. Clin. Microbiol. Rev. 14: 643-658 [Abstract] [Full Text]  
  • Wenisch, C., Moore, C. B., Krause, R., Presterl, E., Pichna, P., Denning, D. W. (2001). Antifungal Susceptibility Testing of Fluconazole by Flow Cytometry Correlates with Clinical Outcome. J. Clin. Microbiol. 39: 2458-2462 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»